The World Health Organization currently recommends combined streptomycin and rifampicin antibiotic treatment as first-line therapy for Mycobacterium ulcerans infections. Alternatives are needed when these are not tolerated or accepted by patients, contraindicated, or neither accessible nor affordable. Despite in vitro effectiveness, clinical evidence for fluoroquinolone antibiotic use against Mycobacterium ulcerans is lacking. We describe outcomes and tolerability of fluoroquinolone-containing antibiotic regimens for Mycobacterium ulcerans in south-eastern Australia.
O’Brien, D. P., McDonald, A., Callan, P., Robson, M., Friedman, N. D., Hughes, A., … Athan, E. (2012). Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: An observational cohort study. PLoS Neglected Tropical Diseases, 6(1). https://doi.org/10.1371/journal.pntd.0001473